Beneficial effects montelukast, cysteinyl-leukotriene receptor antagonist, on renal damage after unilateral ureteral obstruction in rats

Basit Öğe Kaydı
dc.authorid25026476400
dc.authorid24492292800
dc.authorid49963074800
dc.authorid35768988000
dc.authorid6603965905
dc.authorid33768003100
dc.authorid36937882500
dc.authorid12797664300
dc.authorid55259818500
dc.contributor.authorOtunctemur A.
dc.contributor.authorOzbek E.
dc.contributor.authorCakir S.S.
dc.contributor.authorDursun M.
dc.contributor.authorCekmen M.
dc.contributor.authorPolat E.C.
dc.contributor.authorOzcan L.
dc.contributor.authorSomay A.
dc.contributor.authorOzbay N.
dc.date.accessioned20.04.201910:49:12
dc.date.accessioned2019-04-20T21:44:08Z
dc.date.available20.04.201910:49:12
dc.date.available2019-04-20T21:44:08Z
dc.date.issued2015
dc.departmentBayburt Ãœniversitesien_US
dc.description.abstractIntroduction: Ureteral obstruction is a common pathology and caused kidney fibrosis and dysfunction at late period. In this present, we investigated the antifibrotic and antiinflammatory effects of montelukast which is cysteinyl leukotriene receptor antagonist, on kidney damage after unilateral ureteral obstruction(UUO) in rats. Materials and Methods: 32 rats divided four groups. Group 1 was control, group 2 was sham, group 3 was rats with UUO and group 4 was rats with UUO which were given montelukast sodium (oral 10 mg/kg/day). After 14 days, rats were killed and their kidneys were taken and blood analysis was performed. Tubular necrosis, mononuclear cell infiltration and interstitial fibrosis scoring were determined histopathologically in a part of kidneys; nitric oxide(NO), malondialdehyde(MDA) and reduced glutathione(GSH) levels were determined in the other part of kidneys. Urea-creatinine levels were investigated at blood analysis. Statistical analyses were made by the Chi-square test and one-way analysis of variance (ANOVA). Results: There was no difference significantly for urea-creatinine levels between groups. Pathologically, there was serious tubular necrosis and fibrosis in group 3 and there was significantly decreasing for tubular necrosis and fibrosis in group 4(p<0.005). Also, there was significantly increasing for NO and MDA levels; decreasing for GSH levels in group 3 compared the other groups(p<0.005). Conclusion: We can say that montelukast prevent kidney damage with antioxidant effect, independently of NO.en_US
dc.identifier.doi10.1590/S1677-5538.IBJU.2015.02.14
dc.identifier.endpage287
dc.identifier.issn1677-5538
dc.identifier.issue2
dc.identifier.startpage279
dc.identifier.urihttps://dx.doi.org/10.1590/S1677-5538.IBJU.2015.02.14
dc.identifier.urihttps://hdl.handle.net/20.500.12403/777
dc.identifier.volume41
dc.language.isoenen_US
dc.publisherBrazilian Society of Urology
dc.relation.ispartofInternational Braz J Urolen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCysteinyl-leukotriene[supplementary concept]
dc.subjectMontelukast [supplementary concept]
dc.subjectRenal insufficiency
dc.subjectUreteral obstruction
dc.subjectacetic acid derivative
dc.subjectcreatinine
dc.subjectcysteine
dc.subjectcysteinyl-leukotriene
dc.subjectglutathione
dc.subjectleukotriene
dc.subjectleukotriene receptor blocking agent
dc.subjectmalonaldehyde
dc.subjectmontelukast
dc.subjectnitric oxide
dc.subjectprotective agent
dc.subjectquinoline derivative
dc.subjecturea
dc.subjectanimal
dc.subjectantagonists and inhibitors
dc.subjectblood
dc.subjectcomplication
dc.subjectdrug effects
dc.subjectfibrosis
dc.subjectkidney
dc.subjectlipid peroxidation
dc.subjectmale
dc.subjectoxidative stress
dc.subjectpathology
dc.subjectRenal Insufficiency
dc.subjectreproducibility
dc.subjecttreatment outcome
dc.subjectureter obstruction
dc.subjectWistar rat
dc.subjectAcetates
dc.subjectAnimals
dc.subjectCreatinine
dc.subjectCysteine
dc.subjectFibrosis
dc.subjectGlutathione
dc.subjectKidney
dc.subjectLeukotriene Antagonists
dc.subjectLeukotrienes
dc.subjectLipid Peroxidation
dc.subjectMale
dc.subjectMalondialdehyde
dc.subjectNitric Oxide
dc.subjectOxidative Stress
dc.subjectProtective Agents
dc.subjectQuinolines
dc.subjectRats, Wistar
dc.subjectRenal Insufficiency
dc.subjectReproducibility of Results
dc.subjectTreatment Outcome
dc.subjectUrea
dc.subjectUreteral Obstruction
dc.subjectCysteinyl-leukotriene[supplementary concept]
dc.subjectMontelukast [supplementary concept]
dc.subjectRenal insufficiency
dc.subjectUreteral obstruction
dc.subjectacetic acid derivative
dc.subjectcreatinine
dc.subjectcysteine
dc.subjectcysteinyl-leukotriene
dc.subjectglutathione
dc.subjectleukotriene
dc.subjectleukotriene receptor blocking agent
dc.subjectmalonaldehyde
dc.subjectmontelukast
dc.subjectnitric oxide
dc.subjectprotective agent
dc.subjectquinoline derivative
dc.subjecturea
dc.subjectanimal
dc.subjectantagonists and inhibitors
dc.subjectblood
dc.subjectcomplication
dc.subjectdrug effects
dc.subjectfibrosis
dc.subjectkidney
dc.subjectlipid peroxidation
dc.subjectmale
dc.subjectoxidative stress
dc.subjectpathology
dc.subjectRenal Insufficiency
dc.subjectreproducibility
dc.subjecttreatment outcome
dc.subjectureter obstruction
dc.subjectWistar rat
dc.subjectAcetates
dc.subjectAnimals
dc.subjectCreatinine
dc.subjectCysteine
dc.subjectFibrosis
dc.subjectGlutathione
dc.subjectKidney
dc.subjectLeukotriene Antagonists
dc.subjectLeukotrienes
dc.subjectLipid Peroxidation
dc.subjectMale
dc.subjectMalondialdehyde
dc.subjectNitric Oxide
dc.subjectOxidative Stress
dc.subjectProtective Agents
dc.subjectQuinolines
dc.subjectRats, Wistar
dc.subjectRenal Insufficiency
dc.subjectReproducibility of Results
dc.subjectTreatment Outcome
dc.subjectUrea
dc.subjectUreteral Obstruction
dc.titleBeneficial effects montelukast, cysteinyl-leukotriene receptor antagonist, on renal damage after unilateral ureteral obstruction in ratsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu